Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating

141
13
Favorite

Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating

Seekingalpha2022-05-20

Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

141

Report

Comment（13）

Ackw
·2022-05-22
[Happy]
Reply
1
Report
Vincent1968
·2022-05-21
Ok
Reply
Like
Report
Seah CL
·2022-05-21
K
Reply
1
Report
Mic6226
·2022-05-21
Good
Reply
1
Report
Chonky
·2022-05-21
Like please
Reply
2
Report
flyingfish28
·2022-05-20
Pls like
Reply
2
Report
VaanWu
·2022-05-20
Ok
Reply
3
Report
Anzygart
·2022-05-20
Ok
Reply
2
Report
SteadyDoesIt
·2022-05-20
Ok
Reply
2
Report
Investigater
·2022-05-20
Gosh
Reply
1
Report
Investigater
·2022-05-20
Gosh
Reply
3
Report
AlphaSpiker
·2022-05-20
Yeah
Reply
1
Report
AlphaSpiker
·2022-05-20
😀
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2236101020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-20 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2236101020","market":"us","top_or_hot":-1,"title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","media":"Seekingalpha","content":"<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","article_id":"2236101020","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","pubTimestamp":1653055927,"sourceInfo":null,"weMediaInfo":null,"summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax下跌，美国银行发布其唯一的卖出等值评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9028118812,"gmtCreate":1653183823436,"gmtModify":1676535235777,"author":{"id":"4113543702097652","authorId":"4113543702097652","name":"Ackw","avatar":"https://community-static.tradeup.com/news/956158d6a350359839cc00ebf92749eb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4113543702097652","authorIdStr":"4113543702097652"},"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9028118812","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021514753,"gmtCreate":1653086457872,"gmtModify":1676535219244,"author":{"id":"3586393315819735","authorId":"3586393315819735","name":"Vincent1968","avatar":"https://community-static.tradeup.com/news/7f106edb1e06baf3c68462c050422f46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586393315819735","authorIdStr":"3586393315819735"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021514753","repostId":2236101020,"repostType":2,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021596112,"gmtCreate":1653082725336,"gmtModify":1676535218662,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021596112","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021590711,"gmtCreate":1653081812333,"gmtModify":1676535218538,"author":{"id":"4109843165472380","authorId":"4109843165472380","name":"Mic6226","avatar":"https://community-static.tradeup.com/news/642ea3ba3ea408756b94df1fc4fc2d69","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":7,"crmLevelSwitch":1,"idStr":"4109843165472380","authorIdStr":"4109843165472380"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021590711","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021509154,"gmtCreate":1653074379578,"gmtModify":1676535218157,"author":{"id":"3581920930646755","authorId":"3581920930646755","name":"Chonky","avatar":"https://static.tigerbbs.com/2b26c78fb11a9e646bce483ea1b0d6f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581920930646755","authorIdStr":"3581920930646755"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021509154","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021266392,"gmtCreate":1653060537417,"gmtModify":1676535216852,"author":{"id":"3559187437759047","authorId":"3559187437759047","name":"flyingfish28","avatar":"https://static.tigerbbs.com/75507aa8ddf5c1cc85f50faf9c40aa31","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3559187437759047","authorIdStr":"3559187437759047"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021266392","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021285221,"gmtCreate":1653059838063,"gmtModify":1676535216674,"author":{"id":"3578220680898909","authorId":"3578220680898909","name":"VaanWu","avatar":"https://static.tigerbbs.com/0a3dc0391d6255d7d1ab35bde3ce68ab","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578220680898909","authorIdStr":"3578220680898909"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021285221","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021218439,"gmtCreate":1653058721021,"gmtModify":1676535216327,"author":{"id":"4087708380401170","authorId":"4087708380401170","name":"Anzygart","avatar":"https://static.tigerbbs.com/5255e6a87df642eff53b65456895ac13","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087708380401170","authorIdStr":"4087708380401170"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021218439","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021219701,"gmtCreate":1653058355203,"gmtModify":1676535216250,"author":{"id":"4087620073091560","authorId":"4087620073091560","name":"SteadyDoesIt","avatar":"https://static.tigerbbs.com/ab599edb0711e3b18e0dda8931ea8e4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087620073091560","authorIdStr":"4087620073091560"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021219701","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021233520,"gmtCreate":1653056941560,"gmtModify":1676535216040,"author":{"id":"3571011001777364","authorId":"3571011001777364","name":"Investigater","avatar":"https://static.tigerbbs.com/6cc9755a32715757af2686d3467dc2be","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571011001777364","authorIdStr":"3571011001777364"},"htmlText":"Gosh","listText":"Gosh","text":"Gosh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021233520","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021233264,"gmtCreate":1653056934358,"gmtModify":1676535216032,"author":{"id":"3571011001777364","authorId":"3571011001777364","name":"Investigater","avatar":"https://static.tigerbbs.com/6cc9755a32715757af2686d3467dc2be","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571011001777364","authorIdStr":"3571011001777364"},"htmlText":"Gosh","listText":"Gosh","text":"Gosh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021233264","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021239524,"gmtCreate":1653056826068,"gmtModify":1676535216017,"author":{"id":"3573008930783156","authorId":"3573008930783156","name":"AlphaSpiker","avatar":"https://static.tigerbbs.com/7bf4e96af844a7e9da5720d6045b3532","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3573008930783156","authorIdStr":"3573008930783156"},"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021239524","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9021239672,"gmtCreate":1653056809396,"gmtModify":1676535216001,"author":{"id":"3573008930783156","authorId":"3573008930783156","name":"AlphaSpiker","avatar":"https://static.tigerbbs.com/7bf4e96af844a7e9da5720d6045b3532","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3573008930783156","authorIdStr":"3573008930783156"},"htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021239672","repostId":2236101020,"repostType":4,"repost":{"id":"2236101020","pubTimestamp":1653055927,"share":"https://ttm.financial/m/news/2236101020?lang=&edition=fundamental","pubTime":"2022-05-20 22:12","market":"us","language":"en","title":"Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2236101020","media":"Seekingalpha","summary":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America ini","content":"<html><head></head><body><p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.</p><p>BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.</p><p>Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.</p><p>The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.</p><p>Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax&#39;s (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.</p><p>Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Falls As Bank of America Issues Its Only Sell-Equivalent Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall ...</p>\n\n<a href=\"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3841379-nvax-stock-falls-as-bofa-issues-its-only-sell-equivalent-rating","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236101020","content_text":"Novavax (NASDAQ:NVAX) is trading sharply lower in the morning hours Friday after Bank of America initiated its coverage, issuing the COVID-19 vaccine maker its only Sell equivalent rating on Wall Street.BofA analyst Alec W. Stranahan points out that Novavax (NVAX) has lost 59% in the year so far, compared to ~22% decline in the Nasdaq Biotechnology Index (IBB) as expectations for COVID-19 and seasonal flu fell amid sector weakness.Issuing an Underperform rating, he argues that the stock has further room to trade lower despite recent pullback.The firm’s sales projections for the company’s COVID-19 vaccine stand below the consensus, given the bearish outlook on continued booster use, uncertain benefits as a differentiated option and a drop in immunity against new variants such as Omicron.Amid rising competition and stronger data emerging from competitors, the analyst questions the approvability of the Novavax's (NVAX) flu, RSV, and malaria candidates, which are currently in late-stage development.Even with non-conservative estimates for near-term COVID-19 vaccine sales and probability of approval for the flu candidate, the firm issues a $35 per share target on the stock, which stands 80% below the current average price target for the stock on Wall Street.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":141,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}